Galectin Therapeutics Inc. issued a press release on June 23, 2026, regarding the results of a recent Type C meeting held with the U.S. Food and Drug Administration (FDA). The specific details of the meeting outcomes are contained in the attached exhibit. Galectin Therapeutics Inc. is a biotechnology company focused on developing therapies.